Leeds, UK, 5 February 2021: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants, has been named
CHARLOTTESVILLE, Va. —Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA
Oxford, UK, 7th January 2020 – Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $7 million (UK
Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer CAMBRIDGE, UK, BOSTON
Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increase from baseline of 2.7 g/dL at Week 48, which is equal
Data were presented at the American Society of Hematology (ASH) Annual Meeting In an analysis from the 16-week Phase 3 PEGASUS study, 70.7% of patients treated with pegcetacoplan compared to 5.1% of eculizumab-treated patients achieved a
Leeds, UK, 25 November 2020: LUNAC Therapeutics Ltd (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants with minimal
CAMBRIDGE, UK – 10 NOVEMBER 2020. Released today by BioBeat, the seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders
Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH) New analyses from the Phase 3 PEGASUS head-to-head study demonstrate
Second significant value realisation this quarter highlights Epidarex’s successful approach to life science investing Bethesda, MD, USA, and Edinburgh, UK; November 3rd, 2020 – Epidarex